MANAJEMEN SARANA PRASARANA BENGKEL PEMESINAN DI SEKOLAH MENENGAH KEJURUAN NEGERI 3 YOGYAKARTA

Perkembangan Ilmu Pengetahuan dan Teknologi menuntut sekolah untuk dapat menyesuaikan dengan arus perubahan terutama bagi sekolah menengah kejuruan. Lulusan sekolah harus sesuai dengan tuntutan perkembangan zaman. Efektifitas kegiatan kependidikan sekolah dipengaruhi variabel yang menyangkut salah satu aspek yaitu sarana dan prasarana, yang perlu mendapatkan pembinaan dan pengembangan secara berkelanjutan. Tujuan penelitian ini adalah untuk mengetahui manajemen sarana prasarana bengkel pemesinan di SMKN 3 Yogyakarta, dan mengetahui kondisi sarana prasaran bengkel pemesinan SMKN 3 Yogyakarta. Metodologi penelitian yang digunakan adalah penelitian deskriptif kualitatif. Penelitian ini dilakukan di Jurusan Teknik Pemesinan SMKN 3 Yogyakarta. Instrumen yang digunakan berupa wawancara, observasi, dan dokumentasi. Wawancara dilakukan pada kepala jurusan, kepala bengkel dan guru. Data hasil penelitian dianalisis menggunakan teknik analisis deskriptif kualitatif untuk mengetahui manajemen dan kondisi sarana prasarana bengkel pemesinan di SMKN 3 Yogyakarta. Dari hasil penelitian diketahui bahwa manajemen sarana prasarana bengkel pemesinan di SMKN 3 Yogyakarta yang terdiri dari 1) perencanaan sarana prasarana bengkel di SMKN 3 Yogyakarta berjalan sesuai prosedur yang ditetapkan; 2) pengorganisasian berjalan baik sesuai dengan job deskripsi; 3) pelaksanaan sarana prasaran bengkel pemesinan berjalan dengan baik; 4) pengawasan sarana prasarana bengkel pemesinan juga baik dalam pengawasannya oleh kepala bengkel, teknisi dan guru mata pelajaran teknik pemesinan. Adapaun kondisi sarana prasarana bengkel pemesinan di SKMN 3 Yogyakarta terutama alat dan mesin yang cukup baik digunakan dalam pembelajaran praktik. Adapun masalah juga yang dihadapi yaitu kondisi bengkel praktik pemesinan yang saat ini belum memiliki bengkel khusus untuk pembelajaran praktik sehingga masih menggunakan ruangan kelas untuk sementara ini sebagai bengkel pemesinan, hal ini dikarenakan dana yang kurang dalam pengadaan sarana prasarana bengkel. Kata kunci : manajemen sarana prasaran

Automated salamander recognition using deep neural networks and feature extraction

This paper presents a study conducted to recognize salamanders by using their unique body markings based on images. The detection and matching of unique patterns in a salamander’s body can be complex due variability in individual animals size, shape, orientation and also influence from the external enviornment. While traditional methods require time intensive manual image corrections of the salamanders to achieve accurate recognition, in this work we propose a fully automatic techinque for straigthening. We also propose a matching technique based on the corrected images. The convolutional neural network ResNet50 and dense scale-invariant feature transform (DSIFT) are used for belly pattern localization, and matching for salamander recognition

Hyperspectral imaging and machine learning for the prediction of SSC in kiwi fruits

Solids Content (SSC) of the fruits in a non-destructive way. A database is created which includes the hyperspectral data acquired in the visible and near-infrared region (VNIR) and measurements done with a sugar meter.We have applied di?erent machine learning techniques to investigate the correlation between spectral information and the SSC. The models tested were support vector regression (SVR), k-nearest neighbor (KNN), partial least squares (PLS), and multiple linear regression (MLR) with di?erent variable selection techniques and dimensionality reduction. The best model at determining SSC was Uninformative Variable Elimination (UVE)-PLS, which had RMSE = 1.047 °Brix and R2 = 0.39 on the test set

Publisher Correction: Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae.

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper

In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease

Background: Current hepatitis C virus (HCV) therapies may cure ∼60% of infections. They are often contraindicated or poorly tolerated, underscoring the need for safer and more effective drugs. A novel, α-ketoamide-derived, substrate-based inhibitor of the HCV serine protease (SCH446211) was developed. Compared with earlier reported inhibitors of similar chemical class, it has a P1′-P2′ extension which provides extended interaction with the protease active site. The aim of this study was to evaluate the in vitro antiviral activity of SCH446211. Methods: Binding constant of SCH446211 to HCV NS3 protease was measured with the chromogenic substrate in vitro cleavage assay. Cell-based activity of SCH446211 was evaluated in replicon cells, which are Huh-7 hepatoma cells stably transfected with a subgenomic HCV RNA as reported previously. After 72 h of incubation with SCH446211, viral transcription and protein expression were measured by real-time RT-PCR (TaqMan), quantitative in situ hybridization, immunoblot and indirect immunofluorescence. Results: The binding constant of SCH446211 to HCV NS3 protease was 3.8 ± 0.4 nM. HCV replication and protein expression were inhibited by SCH446211 in replicon cells as consistently shown by four techniques. In particular, based on quantitative real-time RT-PCR measurements, the IC50 and IC90 of SCH446211 were estimated to be 40 ± 20 and 100 ± 20 nM (n = 17), respectively. Long-term culture of replicon cells with SCH446211 reduced replicon RNA to <0.1 copy per cell. SCH446211 did not show cellular toxicity at concentrations up to 50 μM. Conclusions: SCH446211 is a potent inhibitor of HCV protease in vitro. Its extended interaction with the HCV NS3 protease active site is associated with potent in vitro antiviral activity. This observation is potentially a useful guide for development of future potent inhibitors against HCV NS3 proteas

Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy

CYP2C19 genotype-guided antiplatelet therapy following percutaneous coronary intervention is increasingly implemented in clinical practice. However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption. In this report, we compare and contrast implementation strategies of 12 early adopters, describing solutions to common problems and initial performance metrics for each program. Key differences between programs included the test result turnaround time and timing of therapy changes which are both related to CYP2C19 testing model and platform used. Sites reported the need for new informatics infrastructure, expert clinicians such as pharmacists to interpret results, physician champions, and ongoing education. Consensus lessons learned are presented to provide a path forward for those seeking to implement similar clinical pharmacogenomics programs within their institutions. This article is protected by copyright

CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.

Background Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel after percutaneous coronary intervention (PCI). We sought to evaluate real-world outcomes with the clinical implementation of CYP2C19-guided antiplatelet therapy after PCI. Methods and Results Data from 9 medical centers where genotyping was performed in the setting of PCI were included. Alternative therapy with prasugrel or ticagrelor was recommended for patients with a CYP2C19 LOF variant. The primary outcome was the composite of major atherothrombotic events (all-cause death, myocardial infarction, ischemic stroke, stent thrombosis, or hospitalization for unstable angina) within 12 months following PCI. Moderate or severe/life-threatening bleeding within 12 months was a secondary outcome. Among 3342 patients, 1032 (31%) were LOF carriers, of whom 571/1032 (55%) were treated with alternative therapy. In LOF carriers, the rate of major atherothrombotic events was lower in patients treated with alternative therapy versus clopidogrel (adjusted HR, 0.56; 95% CI 0.39-0.82). In those without a LOF allele, no difference was observed (adjusted HR, 1.07; 95% CI 0.71-1.60). There was no difference in bleeding with alternative therapy versus clopidogrel in either LOF carriers or those without a LOF allele. Conclusions Real-world data demonstrate lower atherothrombotic risk in CYP2C19 LOF carriers treated with alternative therapy versus clopidogrel and similar risk in those without a LOF allele treated with clopidogrel or alternative therapy. These data suggest that PCI patients treated with clopidogrel should undergo genotyping so that CYP2C19 LOF carriers can be identified and treated with alternative therapy

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Genotyping for CYP2C19 no function alleles to guide antiplatelet therapy after percutaneous coronary intervention (PCI) improves clinical outcomes. Although results for the increased function CYP2C19*17 allele are also reported, its clinical relevance in this setting remains unclear. A collaboration across nine sites examined antiplatelet therapy prescribing and clinical outcomes in 3,342 patients after implementation of CYP2C19-guided antiplatelet therapy. Risk of major atherothrombotic and bleeding events over 12 months after PCI were compared across cytochrome P450 2C19 isozyme (CYP2C19) metabolizer phenotype and antiplatelet therapy groups by proportional hazards regression. Clopidogrel was prescribed to a similar proportion of CYP2C19 normal (84.5%), rapid (82.9%), and ultrarapid metabolizers (80.6%) (P = 0.360). Clopidogrel-treated normal metabolizers (20.4 events/100 patient-years; adjusted hazard ratio (HR) 1.00, 95% confidence interval (CI), 0.75-1.33, P = 0.993) and clopidogrel-treated rapid or ultrarapid metabolizers (19.1 events/100 patient-years; adjusted HR 0.95, 95% CI, 0.69-1.30, P = 0.734) exhibited no difference in major atherothrombotic events compared with patients treated with prasugrel or ticagrelor (17.6 events/100 patient-years). In contrast, clopidogrel-treated intermediate and poor metabolizers exhibited significantly higher atherothrombotic event risk compared with prasugrel/ticagrelor-treated patients (adjusted HR 1.56, 95% CI, 1.12-2.16, P = 0.008). When comparing clopidogrel-treated rapid or ultrarapid metabolizers to normal metabolizers, no difference in atherothrombotic (adjusted HR 0.97, 95% CI, 0.73-1.29, P = 0.808) or bleeding events (adjusted HR 1.34, 95% CI, 0.83-2.17, P = 0.224) were observed. In a real-world setting of genotype-guided antiplatelet therapy, the CYP2C19*17 allele did not significantly impact post-PCI prescribing decisions or clinical outcomes. These results suggest the CYP2C19 *1/*17 and *17/*17 genotypes have limited clinical utility to guide antiplatelet therapy after PCI